Heterodimeric antibodies including binding to cd8
US-2016176969-A1 · Jun 23, 2016 · US
Antibodies with modified isoelectric points
US9605061B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9605061-B2 |
| Application number | US-201414165487-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 27, 2014 |
| Priority date | Jul 29, 2010 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
First claim
Opening claim text (preview).
The invention claimed is: 1. An antibody comprising: a) a variant heavy chain constant domain comprising a variant of SEQ ID NO: 2, wherein said variant comprises amino acid substitutions G137E/G138S/I199T/N203D/K214T/K222T/K274Q/Y296F/Y300F/L309V/A339T/R355Q/N384S/K392N/V397M/Q419E/Del447K, and b) a light chain constant domain selected from the group consisting of SEQ ID NOs: 1, 30, 31 and 32, wherein said numbering is according to EU index. 2. The antibody of claim 1 , wherein said light chain constant domain comprises SEQ ID NO: 1. 3. The antibody of claim 1 , wherein said light chain constant domain comprises SEQ ID NO: 30. 4. The antibody of claim 1 , wherein said light chain constant domain comprises SEQ ID NO: 31. 5. The antibody of claim 1 , wherein said light chain constant domain comprises SEQ ID NO: 32. 6. The antibody of claim 1 , wherein said variant heavy chain constant domain further comprises amino acid substitution N434S. 7. The antibody of claim 1 , wherein said variant heavy chain constant domain further comprises amino acid substitutions M428L/N434S.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
CH2 domain · CPC title
Complete light chain, i.e. VL + CL · CPC title
- C07K16/22Primary
against growth factors {; against growth regulators} · CPC title
CH1 domain · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9605061B2 cover?
- The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
- Who is the assignee on this patent?
- Xencor Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).